Internal Medicine · Salisbury, MD
NPI
1457372310
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
951 Mount Hermon Rd Ste A
Salisbury, MD, 21804
Phone (410) 749-4400
Groups this clinician bills Medicare through
Medicare paid, 2024
$422K
7,089 services
Medicare patients, 2024
1,483
Average age 77
Drug cost, 2024
$3.9M
28,064 prescriptions
Company payments, 2025
$908
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vel Natesan was code 99214 (office e&m - established), 2,579 times for 1,261 patients. In total Vel Natesan billed 7,089 services in 36 codes, and Medicare paid $422K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 2,579 | 1,261 | $53.17 | $137K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,517 | 1,020 | $12.38 | $19K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 1,091 | 1,091 | $128.74 | $140K |
| G0008 Administration of influenza virus vaccine | Office | 293 | 291 | $32.30 | $9,464 |
| 90653 Vaccine Product | Office | 279 | 277 | $80.65 | $23K |
| 99213 Office E&M - Established | Office | 231 | 214 | $47.57 | $11K |
| 96372 Injection Administration | Office | 193 | 38 | $9.36 | $1,807 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 181 | 33 | $0.82 | $149 |
| G0438 Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 122 | 122 | $163.07 | $20K |
| 90677 Vaccine Product | Office | 83 | 83 | $286.24 | $24K |
| G0009 Administration of pneumococcal vaccine | Office | 83 | 83 | $32.30 | $2,681 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 82 | 77 | $206.09 | $17K |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 70 | 61 | $42.42 | $2,970 |
| 93000 Electrocardiogram | Office | 53 | 51 | $8.77 | $465 |
| G0402 Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 44 | 44 | $163.74 | $7,205 |
By year: 2022 $497K for 6,288 services; 2023 $436K for 5,649 services; 2024 $422K for 7,089 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 42 | 40 | $9.29 | $390 |
| 81002 Clinical Chemistry | 13 | 12 | $3.19 | $41.48 |
Medicare prescription drug claims, 2024
In 2024, the drug Vel Natesan prescribed most often to Medicare patients was Rosuvastatin Calcium, with 1,527 prescriptions and refills. In total Vel Natesan wrote 28,064 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 1,527 | 4,167 | 445 | $44K |
| Atorvastatin Calcium Generic | 1,297 | 3,386 | 337 | $19K |
| Amlodipine Besylate Generic | 1,132 | 2,944 | 308 | $10K |
| Levothyroxine Sodium Generic | 1,025 | 2,828 | 277 | $10K |
| Pantoprazole Sodium Generic | 686 | 1,564 | 197 | $11K |
| Olmesartan Medoxomil Generic | 673 | 1,602 | 180 | $23K |
| Metoprolol Succinate Generic | 553 | 1,391 | 142 | $8,823 |
| Tamsulosin Hcl Generic | 536 | 1,271 | 142 | $9,311 |
| Eliquis Apixaban | 494 | 822 | 107 | $463K |
| Potassium Chloride Generic | 484 | 1,081 | 138 | $20K |
| Gabapentin Generic | 448 | 818 | 126 | $6,269 |
| Losartan Potassium Generic | 419 | 1,064 | 113 | $5,362 |
| Jardiance Empagliflozin | 406 | 811 | 97 | $454K |
| Furosemide Generic | 390 | 814 | 116 | $1,697 |
| Fluticasone Propionate Generic | 379 | 688 | 171 | $4,745 |
Brand drugs: 4,023 claims; generic drugs: 23,893 claims; opioid claims: 270.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vel Natesan $908 ($908 in general payments such as food, travel and fees) from 17 companies. The largest payer was Amgen Inc. with $211.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 8 | $211 |
| Lilly USA, LLC LLY | 7 | $140 |
| Novo Nordisk Inc NVO | 6 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $77.5 |
| Scpharmaceuticals Inc. SCPH | 3 | $48.15 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $47.18 |
| Pfizer Inc. PFE | 2 | $37.84 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $37.76 |
| Dexcom, Inc. DXCM | 2 | $37.3 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 2 | $34.51 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.